Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carboplatin is a platinum-based chemotherapeutic agent that exerts its cytotoxic effects primarily through the formation of covalent adducts with DNA. The most significant of these are DNA crosslinks—both intrastrand and interstrand—which disrupt normal cellular processes such as replication and transcription, ultimately leading to cell death. Crosslinked DNA cannot be properly replicated or transcribed, triggering cell cycle arrest and apoptosis. Repair mechanisms exist but are often overwhelmed or defective in cancer cells. The extent and persistence of these lesions correlate with therapeutic efficacy as well as toxicity profiles.
Covalent binding at N7 purines leading to intra- and interstrand crosslinks, disrupting DNA replication and transcription.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA (carboplatin-induced crosslinking).